Overall, we believe using peptides for surface modification of nanoparticles as targeting ligands to the overexpressed ICAM-1 at the inflammatory sites is a promising strategy for effective sepsis management with minimized systemic toxicities, as evidenced by these reports. This evidence concerns the gene ICAM1 and Sepsis.